Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...

Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...

German sci-tech giant Merck is very optimistic about its prospects in the Chinese market and will continue to strengthen its ...

Bernstein has recently initiated Merck & Co Inc (MRK) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on March 11, 2024, Societe Generale had reduced the ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...

Its top-selling treatment, Keytruda, will lose patent protection in a few years. Then Merck will face biosimilar competition ...

Shares of Merck & Co. Inc. MRK inched 0.44% higher to $101.17 Thursday, on what proved to be an all-around mixed trading ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange ...